MedTech MetroAdd to calendar
Thursday, December 3, 2015
5:30 pm – 9:00 pm
Location: Loeb & Loeb, 345 Park Ave, New York, NY 10154
MedTech Metro is an intimate forum and networking series designed to showcase New York’s bioscience and medical technology (Bio/Med) community before an audience of investors, business leaders and health care providers committed to promoting and supporting the Bio/Med industry.
5:30 - 6:30 - Registration / Networking Reception
6:30 - 7:15 - Company Presentations
7:15 - 8:15 - Keynote Presentation
8:15 - 9:00 - Networking
CEO, 21st Century Investors Co-founder, Celgene Corporation
Mr. Isaac Blech established some of the leading companies in the biotechnology industry including Celgene Corporation, the world’s leading hematology/oncology company, ICOS Corporation which created the drug Cialis, Pathogenesis Corporation which created the first inhaled antibiotic approved by the US FDA and added thirty years of life to children with CF, Nova Pharmaceutical Corporation, which created a new treatment for brain cancer and Genetic Systems Corporation which created the first practical diagnostic test for chlamydia, enabling millions of babies to be born around the world that could not have been born without widespread chlamydia testing. The combined value of Mr. Blech’s companies is in excess of $100 billion.
Mr. Blech currently has a new portfolio of nine companies which are pushing the frontiers of medical diagnosis and treatment for patients around the world.
- Mark Punyanitya, Co-founder
- MagnePath is a technology company bridging the divide between digital health and medical device & software development. We have created LiverMap, as a "Virtual Liver Biopsy" to replace invasive diagnostic procedures. Our MRI technology is independent of scanner manufacturer, without the need for needle injections or contrast agents, and can be completed within 5 minutes. The MagnePath platform is offered on a pay-peruse, SaaS model, allowing any Imaging Facility, anywhere, to utilize the latest Imaging Biomarkers, without the need for expensive, long-term contracts. Our team includes expertise in the development of: Imaging Biomarkers, Medical Device & Diagnostics, and Multi-Center Clinical Trials, previously achieving: FDA Approval, Companion Diagnostic Status, and listing as a public company. MagnePath is seeking to raise $2 million in seed funding, in order to conduct a US based pilot study, prepare the first submission to the FDA for regulatory review, and to increase outreach to additional biotech & pharmaceutical companies.
- Nik Tezapsidis, CEO
Neurotez, Inc. is a private corporation whose primary goal is to develop a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk. Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain. This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels. The administration of Leptin inhibits both the production of amyloid beta (Aβ) and also the phosphorylation of tau protein in a variety of in vitro and in vivo systems. Since Aβ and phospho-tau are widely viewed as two of the key factors in Alzheimer’s disease etiology, Leptin represents a highly attractive, multi-functional therapeutic approach. Perhaps most tellingly, Neurotez has demonstrated that the administration of Leptin significantly improves cognition across a variety of measures in transgenic mouse models of AD. Thus, a wide spectrum of preclinical findings strongly supports the likelihood that Leptin augmentation will effectively slow or stop the progression of AD and may even preclude or delay the onset of cognitive decline in pre-impairment individuals. Manufacturing a GMP product and preparation for human trials at Stanford U is underway, while a collaboration with Kinemed, Inc., CA, will address pharmacokinetic and pharmacodynamics aspects for optimum dosing.
- Frank Borchetta, Co-founder
- Repairogen is a skin care company that is using a novel scientifically proven DNA repair technology to develop innovative products. The company is seeking financing to complete the pre-clinical developmental work and produce a final formulation for an anti-aging skin care product line. The company’s propriety technology repairs DNA damage through a unique mechanism of action that enhances the natural DNA repair process. This unique repair platform distinguishes the company from other competitors and gives the companies anti-aging products credibility due to its scientifically proven mechanism of action. The company has used a seed round to confirm proof of concept and initial safety and efficacy studies.